摘要
Context and objective: The COVID-19 pandemic has become a major public health problem and has mobilized many innovative means of diagnosis. The Central African Republic is not spared. The emergence of variants and their impact require health monitoring despite the obligation of vaccination. The purpose of this campaign was to determine the circulation of pending second-wave variants. Patients and Methods: A second mass screening campaign took place from 02 to 22 July 2021 in the main land and river entry points of Bangui (Exit North-PK12, Exit South-PK9, Port Beach) and at the LNBCSP. Antigenic and RT-PCR tests carried out on nasopharyngeal samples made it possible to select strains which were finally sequenced. Results: Of 2687 participants included in the study, 53 (1.97%) were positive for SARS-CoV-2. Thirteen (1.53%) were male and 40 (2.18%) female. The analyses carried out on the LumiraDx analyzer were positive for 109 samples against 53 on the RT-PCR. The prevalence was higher in the most tested age groups (30 to 50 years) with two clusters identified. B.1.617.2 (Delta) variants were predominant (57%). Conclusion: SARS-CoV-2 continues to circulate. The acquisition of automated antigenic tests (LumiraDx®) with sensitivity and specificity close to those of the reference test (RT-PCR) will allow better mass diagnosis for an optimization of the surveillance of COVID-19 in our countries with limited resources. The predominance of the B.1.617.2 (Delta) variant would suggest a third wave in the Central African Republic.
Context and objective: The COVID-19 pandemic has become a major public health problem and has mobilized many innovative means of diagnosis. The Central African Republic is not spared. The emergence of variants and their impact require health monitoring despite the obligation of vaccination. The purpose of this campaign was to determine the circulation of pending second-wave variants. Patients and Methods: A second mass screening campaign took place from 02 to 22 July 2021 in the main land and river entry points of Bangui (Exit North-PK12, Exit South-PK9, Port Beach) and at the LNBCSP. Antigenic and RT-PCR tests carried out on nasopharyngeal samples made it possible to select strains which were finally sequenced. Results: Of 2687 participants included in the study, 53 (1.97%) were positive for SARS-CoV-2. Thirteen (1.53%) were male and 40 (2.18%) female. The analyses carried out on the LumiraDx analyzer were positive for 109 samples against 53 on the RT-PCR. The prevalence was higher in the most tested age groups (30 to 50 years) with two clusters identified. B.1.617.2 (Delta) variants were predominant (57%). Conclusion: SARS-CoV-2 continues to circulate. The acquisition of automated antigenic tests (LumiraDx®) with sensitivity and specificity close to those of the reference test (RT-PCR) will allow better mass diagnosis for an optimization of the surveillance of COVID-19 in our countries with limited resources. The predominance of the B.1.617.2 (Delta) variant would suggest a third wave in the Central African Republic.
作者
Clotaire Donatien Rafaï
Pierre Somse
Wilfrid Sylvain Nambei
Ernest Lango-Yaya
Marie-Roseline Darnycka Belizaire
Ulrich Vickos
Narcisse Patrice Komas
Oscar Senzongo
Luc Salva Heredeibona
Ulrich Jeffrey Kotemossoua
Rabbi Mermoz Senekian
Simon Pounguinza
Jephté Estimé Kaleb Kandou
Christian-Diamant Mossoro-Kpinde
Laurent Bélec
Jean De Dieu Longo
Norbert Richard Ngbale
Abdoulaye Sepou
François-Xavier Mbopi-Keou
Gérard Grésenguet
Boniface Koffi
Clotaire Donatien Rafaï;Pierre Somse;Wilfrid Sylvain Nambei;Ernest Lango-Yaya;Marie-Roseline Darnycka Belizaire;Ulrich Vickos;Narcisse Patrice Komas;Oscar Senzongo;Luc Salva Heredeibona;Ulrich Jeffrey Kotemossoua;Rabbi Mermoz Senekian;Simon Pounguinza;Jephté Estimé Kaleb Kandou;Christian-Diamant Mossoro-Kpinde;Laurent Bélec;Jean De Dieu Longo;Norbert Richard Ngbale;Abdoulaye Sepou;François-Xavier Mbopi-Keou;Gérard Grésenguet;Boniface Koffi(National Laboratory of Clinical Biology and Public Health, Bangui, Central African Republic;Faculty of Health Sciences, University of Bangui, Bangui, Central African Republic;Ministry of Health and Population, Bangui, Central African Republic;World Health Organization, Bangui, Central African Republic;Institut Pasteur de Bangui, Bangui, Central African Republic;Virology Laboratory, Georges Pompidou European Hospital, Université Paris Cité, Paris, France;Hôpital Communautaire of Bangui, Bangui, Central African Republic;Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon)
